The top selling biologics market is projected to be worth USD 156 billion by 2030

Owing to the numerous benefits offered by biologics, this drug class has become an integral part of the overall pharmaceutical industry, having captured a significant market share over the past couple of decades

Roots Analysis has announced the addition of the “Top Selling Biologics Market, 2021 – 2030” report to its list of offerings.

Over the years, around 200 biologics have been approved for the treatment of various disease indications in the US and Europe. In 2020, 18 new biologics received approval by the USFDA. Despite their complex and cost intensive manufacturing protocols, biopharmaceuticals (once approved) are considered to be highly profitable assets. In the recent past, many biological interventions have achieved blockbuster status (in some cases, registering revenues worth over USD 4 billion a year); prominent examples include (arranged in decreasing order of 2020 revenues) Humira®, Keytruda®, Stelara®, Opdivo®, Avastin®, Trulicity®, Enbrel®, Ocrevus™ and Rituxan®.

To order this 320+ page report, which features 190+ figures and 195+ tables, please visit this https://www.rootsanalysis.com/reports/top-selling-biologics-market.html

Leave a Reply

Your email address will not be published. Required fields are marked *